Michael DesJardin
Chief Tech/Sci/R&D Officer chez HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Profil
Actuellement, Michael A. DesJardin occupe le poste de vice-président exécutif des opérations techniques et de la qualité chez Horizon Therapeutics Plc et de premier vice-président des opérations techniques chez Horizon Pharmaceutical LLC (une filiale d'Horizon Therapeutics Plc). Il est également Senior Vice President-Technical Operations chez Horizon Pharmaceutical LLC. Il a auparavant occupé le poste de premier vice-président du développement des produits chez Jazz Pharmaceuticals Plc et celui de directeur exécutif de la recherche et du développement des implants chez ALZA Corp. M. DesJardin a obtenu un diplôme de premier cycle à l'Université de Californie, Berkeley.
Postes actifs de Michael DesJardin
| Sociétés | Poste | Début |
|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 01/02/2017 |
Anciens postes connus de Michael DesJardin
| Sociétés | Poste | Fin |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Chief Tech/Sci/R&D Officer | 01/10/2016 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/03/2015 |
| ALZA CORPORATION | Chief Tech/Sci/R&D Officer | - |
Formation de Michael DesJardin
| University of California, Berkeley | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
ALZA Corp.
 ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
